Display options
Cite
Opie LH. Calcium antagonists post-infarction: the significance of experimental studies on potentially lethal early ischemic ventricular arrhythmias. Cardiovasc Drugs Ther. 1991;5(4):671-5doi: 10.1007/BF03029739.
Opie, L. H. (1991). Calcium antagonists post-infarction: the significance of experimental studies on potentially lethal early ischemic ventricular arrhythmias. Cardiovascular drugs and therapy, 5(4), 671-5. https://doi.org/10.1007/BF03029739
Opie, L H. "Calcium antagonists post-infarction: the significance of experimental studies on potentially lethal early ischemic ventricular arrhythmias." Cardiovascular drugs and therapy vol. 5,4 (1991): 671-5. doi: https://doi.org/10.1007/BF03029739
Opie LH. Calcium antagonists post-infarction: the significance of experimental studies on potentially lethal early ischemic ventricular arrhythmias. Cardiovasc Drugs Ther. 1991 Aug;5(4):671-5. doi: 10.1007/BF03029739. PMID: 1679660.
Copy Download .nbib Format: NLM
Share it on

Cardiovasc Drugs Ther. 1991 Aug;5(4):671-5. doi: 10.1007/BF03029739.

Calcium antagonists post-infarction: the significance of experimental studies on potentially lethal early ischemic ventricular arrhythmias.

Cardiovascular drugs and therapy

L H Opie

PMID: 1679660 DOI: 10.1007/BF03029739

Abstract

The DAVIT-II trial has shown that the verapamil type of calcium antagonist can beneficially be used in post-infarct patients. A recent re-analysis suggests that verapamil may also prevent post-infarct sudden death. There are good theoretical reasons to suppose that calcium antagonists should help prevent ventricular fibrillation. If calcium antagonist agents could be found which have negligible negative inotropic effects, such drugs might be ideal for further testing in the post-infarct phase.

References

  1. Circulation. 1991 Jan;83(1):336-8 - PubMed
  2. J Cardiovasc Pharmacol. 1990 Mar;15(3):347-52 - PubMed
  3. Am J Cardiol. 1991 Jun 1;67(15):1295-7 - PubMed
  4. J Am Coll Cardiol. 1990 Nov;16(6):1327-32 - PubMed
  5. Circulation. 1991 Feb;83(2):622-34 - PubMed
  6. Circulation. 1991 Jan;83(1):52-60 - PubMed
  7. Am J Cardiol. 1981 Nov;48(5):851-7 - PubMed
  8. Ann N Y Acad Sci. 1988;522:464-77 - PubMed
  9. Circ Res. 1987 Aug;61(2):157-65 - PubMed
  10. Cardiovasc Drugs Ther. 1987 Dec;1(4):335-42 - PubMed
  11. Annu Rev Med. 1990;41:231-8 - PubMed
  12. Cardiovasc Drugs Ther. 1990 Aug;4 Suppl 5:1047-68 - PubMed
  13. Circulation. 1988 Oct;78(4):1047-59 - PubMed
  14. Cardiovasc Drugs Ther. 1990 Jun;4(3):675-9 - PubMed
  15. Circ Res. 1990 Jun;66(6):1461-73 - PubMed
  16. Circulation. 1990 Dec;82(6):2254-7 - PubMed
  17. Am J Cardiol. 1990 Oct 1;66(10):779-85 - PubMed
  18. J Mol Cell Cardiol. 1987 Oct;19 Suppl 5:13-21 - PubMed
  19. N Engl J Med. 1988 Aug 18;319(7):385-92 - PubMed
  20. Lancet. 1989 Jun 10;1(8650):1309-12 - PubMed
  21. J Cardiovasc Pharmacol. 1991 Jan;17(1):74-82 - PubMed
  22. Cardiovasc Res. 1991 Jan;25(1):49-57 - PubMed
  23. Circ Res. 1988 Mar;62(3):554-62 - PubMed
  24. BMJ. 1989 Nov 11;299(6709):1187-92 - PubMed
  25. Cardiovasc Drugs Ther. 1990 Jun;4(3):731-6 - PubMed
  26. Br J Clin Pharmacol. 1986;21 Suppl 2:197S-204S - PubMed

Substances

MeSH terms

Publication Types

LinkOut - more resources